74,834 Shares in Cellebrite DI Ltd. (NASDAQ:CLBT) Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC acquired a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 74,834 shares of the company’s stock, valued at approximately $648,000.

Other institutional investors have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Cellebrite DI by 44.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,091 shares of the company’s stock worth $115,000 after purchasing an additional 4,672 shares during the period. Meitav Investment House Ltd. bought a new stake in Cellebrite DI during the 3rd quarter valued at about $2,399,000. Clal Insurance Enterprises Holdings Ltd purchased a new stake in Cellebrite DI in the 3rd quarter valued at about $50,270,000. Mawer Investment Management Ltd. grew its stake in Cellebrite DI by 8.4% in the 3rd quarter. Mawer Investment Management Ltd. now owns 323,310 shares of the company’s stock worth $2,473,000 after acquiring an additional 25,159 shares in the last quarter. Finally, Jump Financial LLC increased its position in shares of Cellebrite DI by 78.9% during the third quarter. Jump Financial LLC now owns 67,800 shares of the company’s stock worth $519,000 after acquiring an additional 29,900 shares during the period. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

Cellebrite DI stock traded down $0.13 during trading hours on Friday, reaching $10.72. The stock had a trading volume of 319,999 shares, compared to its average volume of 643,243. The company has a market cap of $2.20 billion, a price-to-earnings ratio of -24.93, a PEG ratio of 1.91 and a beta of 1.51. The business’s 50 day moving average price is $11.23 and its 200-day moving average price is $9.44. Cellebrite DI Ltd. has a 52 week low of $5.22 and a 52 week high of $12.50.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. Cellebrite DI had a negative net margin of 24.94% and a positive return on equity of 173.14%. The firm had revenue of $93.01 million during the quarter, compared to analyst estimates of $85.43 million. On average, sell-side analysts forecast that Cellebrite DI Ltd. will post 0.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CLBT has been the subject of a number of research reports. William Blair upgraded Cellebrite DI from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 13th. Needham & Company LLC raised their price target on Cellebrite DI from $13.00 to $13.50 and gave the company a “buy” rating in a research note on Thursday, March 28th. Bank of America upped their price objective on shares of Cellebrite DI from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Craig Hallum raised their target price on shares of Cellebrite DI from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, April 1st. Finally, Lake Street Capital assumed coverage on shares of Cellebrite DI in a research report on Friday, April 19th. They issued a “buy” rating and a $13.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $12.42.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.